Education
About Us
Working with TipRanks
Follow Us
Incyte Corp (INCY)
NASDAQ:INCY
Earnings Data
Report Date
May 05, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
1.42Last Year’s EPS
1.16Same Quarter Last Year
Moderate Buy
Based on 17 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presents a broadly positive commercial and pipeline narrative: strong 2025 revenue growth, robust core business expansion (ex-Jakafi), multiple high-impact late-stage programs, and constructive 2026 guidance. Offsetting risks include an Opsilora PN setback requiring another study, rising R&D spending to support numerous pivotal trials, pricing/formulary tradeoffs, and the need to successfully launch and gain approvals for several products to replace Jakafi over the coming years. Overall, the positives—notably broad-based revenue growth, accelerating non-Jakafi franchises, and deepened late-stage pipeline—outweigh the challenges and execution risks outlined.Company Guidance
Strong Top-Line Growth
Total revenues of $1.51B in Q4 2025 (up 28% YoY) and $5.14B for full-year 2025 (up 21% YoY). Product/net sales of $1.22B in Q4 (up 20% YoY) and $4.35B for the full year (up 20% YoY).
Core Business Expansion (ex-Jakafi)
Core business (excluding Jakafi) delivered approximately $1.26B in sales, representing a ~53% increase versus 2024, driven primarily by Opsilora, Nictimbo, and Manjovi.
Jakafi Performance and Visibility
Jakafi sales: Q4 $828M (up 7% YoY) and full-year $3.093B (up 11% YoY). Prescriptions increased 11% in Q4 and 9% for the full year. 2026 net sales guidance for Jakafi of $3.22B–$3.27B with prescriptions expected to grow high single digits.
Opsilora Momentum
Opsilora net sales Q4 $207M (up 28% YoY) and FY $678M (up 33% YoY). U.S. AD prescriptions +24% and vitiligo +15%. Pediatric AD launch already annualizing ~ $30M. International Opsilora/vitiligo sales doubled to $130M in 2025. 2026 sales guide $750M–$790M (~15% growth at midpoint).
Hematology & Oncology Surge
Hematology/oncology product sales Q4 $187M (up 121% YoY) and FY $583M (up 83% YoY). Nictimbo first-year sales ~$152M (13,000 infusions across >1,400 patients). Manjovi sales +20% driven by follicular lymphoma launch; Phase III frontline DLBCL results showed a 25% PFS improvement vs R‑CHOP.
Robust Pipeline Advancement and Regulatory Activity
Multiple late-stage moves: 14 pivotal trials across 7 assets expected underway by end of 2026; regulatory submissions filed (Jakafi XR, Opsilora, povastatinib MA in EU); tafasitamab approved in Europe and Japan and positive FRONT MIND phase III data shared.
Notable Oncology & Targeted Therapy Data
KRAS G12D inhibitor (seven34) showed 37% ORR and 78% disease control rate at planned phase 3 dose in predominantly late-line PDAC; phase 3 in first-line PDAC planned to start Q1 2026. Initiated phase 3 for TGFβ2 x PD‑1 bispecific in MSS colorectal cancer.
2026 Guidance and Financial Discipline
Full-year 2026 revenue guidance set at $4.77B–$4.94B (up 10%–13% YoY). Core ex-Jakafi sales guidance $1.57B–$1.69B (≈30% growth at midpoint). Expected FY GAAP R&D + SG&A operating expenses $3.495B–$3.675B; R&D expected ~+10% to advance late-stage programs while SG&A remains roughly flat.
INCY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
INCY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 10, 2026 | $109.03 | $100.05 | -8.24% |
Oct 28, 2025 | $93.08 | $91.65 | -1.54% |
Jul 29, 2025 | $70.16 | $77.38 | +10.29% |
Apr 29, 2025 | $59.52 | $60.43 | +1.53% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Incyte Corp (INCY) report earnings?
Incyte Corp (INCY) is schdueled to report earning on May 05, 2026, Before Open (Confirmed).
What is Incyte Corp (INCY) earnings time?
Incyte Corp (INCY) earnings time is at May 05, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is INCY EPS forecast?
INCY EPS forecast for the fiscal quarter 2026 (Q1) is 1.42.